This review synthesized evidence from multiple studies, identifying active TCMS compounds—such as astragaloside IV, notoginsenoside, magnolol, pterostilbene, and triptolide—and formulations like Simiao Powder and Bushen Huoxue Prescription—that regulate NLRP3 inflammasome activation to combat CKD. The gene discussed is NLRP3; the disease is chronic kidney disease.